biopharmadive.com· Jonathan Gardner·· 3 hours agoPickScore49
Belgian startup revives Galapagos CAR-T research
Belgian startup revives Galapagos CAR-T research
In brief
Lakefront Biotherapeutics, formerly Galapagos, has sold its cell therapy programmes to Belgian startup Armed Cell Therapeutics for 8 million euros up front, with up to $230 million more in future payments. The deal covers two armed CAR-T therapies nearing human testing in non-Hodkin lymphoma and small cell lung cancer, plus three undisclosed preclinical projects. Armed Cell named Willemijn Kremer, a former Galapagos cell therapy executive, as CEO, replacing interim CEO Paul Stoffels.
Why it matters
Revives shelved CAR-T programmes under a new company after Galapagos wound down its cell therapy research.
Source: biopharmadive.com · biopharmadive.com